Odnass — Redefining Early Cancer Detection

Most cancers are caught too late. Odnass is working to change that.
Every year, more than 20 million people are diagnosed with cancer and nearly 10 million die — outcomes that are strongly linked to how late the disease is found. Earlier detection remains one of the most powerful levers we have to improve survival and ease the global burden of the disease.

Odnass is developing a next-generation blood test designed to detect multiple cancers at their earliest, pre-symptomatic stage. Where many liquid-biopsy platforms depend on complex sequencing workflows, Odnass takes a different approach: direct detection and analysis of cell-free DNA (cfDNA) in plasma, using a proprietary protocol built for sensitivity, reproducibility, and cost efficiency.

What sets Odnass apart
Direct cfDNA detection — a streamlined protocol that cuts analytical complexity and enables testing to scale.
AI-driven predictive modelling — deep learning and graph neural networks integrate biological, clinical, and environmental signals to sharpen predictive accuracy.
Secure health-data architecture — infrastructure designed for transparent, tamper-resistant handling of sensitive medical data.
Built for global reach — a cost-efficient platform designed to serve both advanced healthcare systems and underserved regions.

The platform is designed for population-level screening, monitoring of high-risk individuals, occupational-exposure programs, and integration with established screening pathways.

Odnass is advancing through its proof-of-concept phase — validating the core technology, expanding its IP portfolio, and building strategic partnerships across the global diagnostics ecosystem.

Our vision: a world where cancer is found earlier, treatment begins sooner, and survival improves for millions.

📩 velimir.p@odnass.com · admin@odnass.com

Odnass Pty Ltd

Org chart

Teams

Offices

Odnass Pty Ltd

Org chart

Teams

Offices

Related companies